These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38117233)

  • 1. Cell-Free DNA Maps Tissue Injury and Correlates with Disease Severity in Lung Transplant Candidates.
    Balasubramanian S; Richert ME; Kong H; Fu S; Jang MK; Andargie TE; Keller MB; Alnababteh M; Park W; Apalara Z; Sun J; Redekar N; Orens J; Aryal S; Bush EL; Cantu E; Diamond J; Shah P; Yu K; Nathan SD; Agbor-Enoh S
    Am J Respir Crit Care Med; 2024 Mar; 209(6):727-737. PubMed ID: 38117233
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD).
    Keller M; Bush E; Diamond JM; Shah P; Matthew J; Brown AW; Sun J; Timofte I; Kong H; Tunc I; Luikart H; Iacono A; Nathan SD; Khush KK; Orens J; Jang M; Agbor-Enoh S
    J Heart Lung Transplant; 2021 Jun; 40(6):488-493. PubMed ID: 33814284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
    Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
    Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
    [No Abstract]   [Full Text] [Related]  

  • 4. Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study.
    Lederer DJ; Kawut SM; Wickersham N; Winterbottom C; Bhorade S; Palmer SM; Lee J; Diamond JM; Wille KM; Weinacker A; Lama VN; Crespo M; Orens JB; Sonett JR; Arcasoy SM; Ware LB; Christie JD;
    Am J Respir Crit Care Med; 2011 Nov; 184(9):1055-61. PubMed ID: 21799077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung Transplant.
    Porteous MK; Ky B; Kirkpatrick JN; Shinohara R; Diamond JM; Shah RJ; Lee JC; Christie JD; Kawut SM
    Am J Respir Crit Care Med; 2016 Jun; 193(12):1392-400. PubMed ID: 26745666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation.
    Agbor-Enoh S; Wang Y; Tunc I; Jang MK; Davis A; De Vlaminck I; Luikart H; Shah PD; Timofte I; Brown AW; Marishta A; Bhatti K; Gorham S; Fideli U; Wylie J; Grimm D; Goodwin N; Yang Y; Patel K; Zhu J; Iacono A; Orens JB; Nathan SD; Marboe C; Berry GJ; Quake SR; Khush K; Valantine HA
    EBioMedicine; 2019 Feb; 40():541-553. PubMed ID: 30692045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bronchial Culture Growth From the Donor and Recipient as Predictive Factors in the Detection of Primary Graft Dysfunction and Pneumonia After Lung Transplant.
    Atagun Guney P; Uygun Kizmaz Y
    Exp Clin Transplant; 2022 Oct; 20(10):930-936. PubMed ID: 35607803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free DNA in human ex vivo lung perfusate as a potential biomarker to predict the risk of primary graft dysfunction in lung transplantation.
    Kanou T; Nakahira K; Choi AM; Yeung JC; Cypel M; Liu M; Keshavjee S
    J Thorac Cardiovasc Surg; 2021 Aug; 162(2):490-499.e2. PubMed ID: 32928548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation.
    Diamond JM; Meyer NJ; Feng R; Rushefski M; Lederer DJ; Kawut SM; Lee JC; Cantu E; Shah RJ; Lama VN; Bhorade S; Crespo M; Demissie E; Sonett J; Wille K; Orens J; Weinacker A; Weill D; Arcasoy S; Shah PD; Belperio JA; Wilkes D; Ware LB; Palmer SM; Christie JD;
    Am J Respir Crit Care Med; 2012 Sep; 186(6):546-52. PubMed ID: 22822025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival.
    Newton CA; Kozlitina J; Lines JR; Kaza V; Torres F; Garcia CK
    J Heart Lung Transplant; 2017 Aug; 36(8):845-853. PubMed ID: 28262440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal one-year post-lung transplant spirometry is a significant predictor of increased mortality and chronic lung allograft dysfunction.
    Paraskeva MA; Borg BM; Paul E; Fuller J; Westall GP; Snell GI
    J Heart Lung Transplant; 2021 Dec; 40(12):1649-1657. PubMed ID: 34548197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model.
    Agopian VG; Harlander-Locke MP; Markovic D; Dumronggittigule W; Xia V; Kaldas FM; Zarrinpar A; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2018 May; 153(5):436-444. PubMed ID: 29261831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury.
    Bazemore K; Rohly M; Permpalung N; Yu K; Timofte I; Brown AW; Orens J; Iacono A; Nathan SD; Avery RK; Valantine H; Agbor-Enoh S; Shah PD
    J Heart Lung Transplant; 2021 Nov; 40(11):1454-1462. PubMed ID: 34344623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial Differences in Donor-Derived Cell-Free DNA and Mitochondrial DNA After Heart Transplantation, on Behalf of the GRAfT Investigators.
    Shah P; Agbor-Enoh S; Lee S; Andargie TE; Sinha SS; Kong H; Henry L; Park W; McNair E; Tchoukina I; Shah KB; Najjar SS; Hsu S; Rodrigo ME; Jang MK; Marboe C; Berry GJ; Valantine HA;
    Circ Heart Fail; 2024 Apr; 17(4):e011160. PubMed ID: 38375637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of lung transplantation on diastolic dysfunction in recipients with pretransplant pulmonary hypertension.
    Aggarwal R; Potel KN; Jackson S; Lemke NT; Kelly RF; Soule M; Diaz-Gutierrez I; Shumway SJ; Patil J; Hertz M; Nijjar PS; Huddleston SJ
    J Thorac Cardiovasc Surg; 2024 May; 167(5):1643-1653.e2. PubMed ID: 37741317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretransplant Opioid Use and Survival After Lung Transplantation.
    Vahidy S; Li D; Hirji A; Kapasi A; Weinkauf J; Laing B; Lien D; Halloran K
    Transplantation; 2020 Aug; 104(8):1720-1725. PubMed ID: 32732852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organizing pneumonia is associated with molecular allograft injury and the development of antibody-mediated rejection.
    Keller MB; Tian X; Jang MK; Meda R; Charya A; Ozisik D; Berry GJ; Marboe CC; Kong H; Ponor IL; Aryal S; Orens JB; Shah PD; Nathan SD; Agbor-Enoh S
    J Heart Lung Transplant; 2024 Apr; 43(4):563-570. PubMed ID: 37972825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
    Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
    Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of total ischaemic time and disease severity class on graft function after bilateral lung transplantation.
    Aburahma K; de Manna ND; Boethig D; Franz M; Iablonskii P; Heise EL; Bobylev D; Avsar M; Greer M; Schwerk N; Sommer W; Welte T; Haverich A; Warnecke G; Kuehn C; Salman J; Ius F
    Eur J Cardiothorac Surg; 2023 Jun; 63(6):. PubMed ID: 37171893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of extracorporeal membrane oxygenation as a bridge to lung transplantation.
    Toyoda Y; Bhama JK; Shigemura N; Zaldonis D; Pilewski J; Crespo M; Bermudez C
    J Thorac Cardiovasc Surg; 2013 Apr; 145(4):1065-1071. PubMed ID: 23332185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.